Abstracts tagged "systemic lupus erythematosus (SLE) and tacrolimus"

Abstract Number: 1920 • 2017 ACR/ARHP Annual Meeting
Tacrolimus Induces Remission in Refractory and Relapsing Lupus Nephritis By Decreasing P-Glycoprotein Expression and Function on Peripheral Blood Lymphocytes
Vikas Gupta, Sukesh Edavalath, Mohit Kumar Rai, Harshit Singh, Saurabh Chaturvedi and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: About 15-30% of Lupus Nephritis (LN) patients do not respond to first-line immunosuppressive therapy. P-glycoprotein (P-gp) mediated efflux of corticosteroids (CS) may contribute to…
Abstract Number: 2608 • 2017 ACR/ARHP Annual Meeting
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers
Chiara Tani¹, Miguel Martin-Cascon², Mériem Belhocine³, Roberta Vagelli¹, Chiara Stagnaro⁴, Guillermo Ruiz-Irastorza⁵, Nathalie Costedoat-Chalumeau³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Barakaldo, Spain, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: there is no consensus on the use of Tacrolimus (TAC) in patients with SLE; clinical studies on TAC, including all the RCT, are mostly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].